Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting : vimarsana.com

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT --

-- Two patients will share their real-world experience living with TED and being... | June 5, 2023

Related Keywords

Olmsted County , Minnesota , United States , Chicago , Illinois , Jeffreyw Sherman , Malini Gupta , Instagram , Duke University Health System , European Group On Grave Orbitopathy , Nasdaq , Linkedin , Visa , Drug Administration , Twitter , Endocrine Society , Facebook , Horizon Therapeutics , Thyroid Eye Disease , Safety Results , Placebo Controlled Multicenter Trial , Oral Presentation , Multicenter Trial , Hearing Related Issues Associated , Grave Disease , Hearing Related Adverse Events , Teprotumumab Oncology Clinical Trials , Teprotumumab Pooled Efficacy , European Study Sites Participating , Inactive Thyroid Eye Disease Patient Journey , Eye Disease , Early Diagnosis , Duke University Health , Treatment Experience , Exhibit Hall , Inflammatory Bowel Disease , Full Prescribing Information , Thyroid Associated , Grave Disease Is Mediated Through , Insulin Like Growth Factor , Grave Orbitopathy , Clinical Practice Guidelines , Medical Management , European Group , Horizon Therapeutics Public Limited Company Stock Exchange , Ews , Nformation , Ress Release , Epezza , Hase , , Rial , Esults , O , E , Hared , N , Ral , Resentation , Une , 7 , T , Wo , Atients , Ill , Hare , Heir , Xperience , Iving , Ith , Ed , Nd Hznp Ie00bqpvqz61 ,